Investor Relations & Capital Introduction Services in Ireland

Irish startups raised approximately €992 million across 319 companies in 2025, an increase of just €14 million on the previous year. Annual funding has now settled into a €900 million to €1 billion range following the 2021 peak, and the number of companies raising edged up from 307 to 319.

The stability of that headline conceals a market pulling apart at both ends. A record 211 companies raised up to €1 million during the year, while momentum into Series A and beyond continued to lag. The mid-market that normally connects those two positions has thinned considerably: a small number of companies raised very large rounds, a large number raised very small ones, and the seed-to-Series-A range in between has been hollowing out.

Global Capital Network provides investor relations and capital introduction services for companies raising in Ireland, and for allocators seeking structured access to Irish dealflow. Where a market's weakness sits at one identifiable stage, the value of an introduction depends almost entirely on whether it addresses that stage or bypasses it.

Capital Raising & Investor Introductions in Ireland

The distribution across the year was extraordinarily uneven. The first quarter alone saw 69 companies raise approximately €616 million, the strongest opening quarter for Irish startup funding in a decade. The remaining nine months produced roughly €376 million across 250 companies. Close to two thirds of the year's capital arrived in its first three months.

For founders, that pattern is a caution against reading annual totals as a guide to conditions. A company raising in the second half of 2025 was operating in a materially tighter market than the yearly figure implies, and timing has become a more significant variable in Ireland than in most European markets.

Life sciences was the strongest funded sector during the year, drawing on Ireland's established pharmaceutical and medical device base. Artificial intelligence gained momentum, with 99 state-supported startups incorporating AI centrally into their product. Energy and clean technology moved sharply the other way, falling from approximately €328 million in 2024 to around €41 million in 2025, reflecting the absence of the large capital-intensive rounds that had carried the previous year.

Dublin accounted for approximately €667.5 million across 192 companies, representing around 60% of funded companies and 67% of total investment value. Companies outside Dublin raised roughly €210.1 million, with Galway, Louth, Cork, Wicklow and Antrim the strongest performing regional centres.

Female-founded companies recorded a notable shift in participation: 82 raised funding in 2025, close to double the previous year and the highest level since 2017, though total capital to those companies fell from approximately €145 million to €131 million.

GCN supports Irish companies across seed, growth and later stages, with particular attention to the Series A transition where the domestic market is thinnest.

Pitch Deck Design & Fundraising Preparation

The hollowing of Ireland's mid-market changes what preparation must accomplish. A company that has raised under €1 million with state support and is now approaching a €5 to €15 million round is entering the part of the market where domestic capacity is weakest, and the investors capable of writing that cheque are frequently outside Ireland.

GCN works with founders on that transition specifically. Whether the commercial evidence is strong enough to interest an international lead. Whether the market opportunity is framed against Ireland alone, which reads as limiting, or against Europe and North America with support for the claim. Whether the financial model holds if the round takes longer than planned, which in the current Irish market it frequently does.

For life sciences companies, Ireland's strongest funded category, preparation extends to clinical pathway, regulatory strategy, and the capital required to reach each milestone. These are the rounds most likely to require specialist international investors, and those allocators assess against global comparables rather than Irish ones.

Companies emerging from research institutions face an additional requirement around intellectual property position and commercialisation arrangements. Clarity here shortens diligence materially.

Investor Events, Dinners & Networking in Ireland

Ireland's investor community is concentrated in Dublin, with genuine regional activity in Cork, Galway and the border counties. The country is small enough that a well-composed room can reach a meaningful proportion of relevant domestic capital in a single evening.

GCN convenes private investor dinners and closed sessions matched by sector and stage, with mandates verified in advance. For companies approaching Series A, we deliberately compose rooms that include international allocators alongside domestic funds, because that reflects where the round will realistically originate.

Our programming addresses where Irish capital is concentrated: life sciences and medical technology, applied artificial intelligence, enterprise software, and financial technology. Sessions are scheduled around the established Irish and European calendar so that visiting allocators can participate without arranging separate travel.

Investor Webinars & Digital Capital Access

Given the shortage of domestic capital at Series A and beyond, reaching international allocators is a structural requirement for Irish companies rather than an optional extension.

GCN runs online investor sessions connecting Irish founders with allocators across Europe and North America. These are structured for assessment rather than exposure, with short presentations, protected question time, and follow-up routed only to investors who signal genuine interest.

Hybrid formats pair a Dublin gathering with remote attendance, extending reach to London, Boston, New York and San Francisco. Ireland's transatlantic orientation matters here: for many Irish companies, particularly in life sciences and enterprise software, the natural growth investor is American rather than European.

Services for Investors in Ireland

For allocators, Ireland offers an English-speaking eurozone jurisdiction with a sophisticated regulatory environment, a substantial pharmaceutical and medical device base, and a dense concentration of international technology operations that function as customers, partners and eventual acquirers.

The structural gap is also the clearest opportunity. With a record number of companies raising small rounds and a documented shortage of capital at Series A, investors positioned at that stage face limited competition for companies that have already demonstrated early traction under state-supported programmes.

The volatility should be understood too. Nearly two thirds of 2025 funding arrived in a single quarter, which means market conditions can shift quickly and annual figures are a poor guide to the environment in any given month.

GCN provides curated dealflow filtered against stated criteria rather than general distribution, and remains involved through diligence rather than stepping back at introduction.

GCN Deal Flow Platform & Investor Matching

Our platform organises Irish opportunities by sector, stage, geography and thesis. Stage filtering carries particular weight given how sharply the market divides between sub-€1 million rounds and large outliers, with comparatively little in between.

Matching operates on cheque size, stage preference, sector mandate and geographic scope, with attention to whether a company's realistic lead investor is Irish, European or North American.

Why Ireland Is Attractive for Investors

Early-stage formation is genuinely strong. A record 211 companies raised up to €1 million in 2025, supported by an unusually active public funding infrastructure, creating a broad pipeline of companies with early validation.

Participation is broadening. 319 companies raised funding in 2025 against 307 in 2024, and female-founded companies raising capital nearly doubled to 82, the highest level since 2017.

Sector depth is real where it exists. Life sciences was the strongest funded category in 2025, drawing on an established pharmaceutical and medical device manufacturing base rather than an aspirational cluster.

The Series A gap is the opening. With momentum lagging at Series A and beyond, allocators with growth capacity face materially less competition for Irish companies that have already proven early traction.

Partner with Global Capital Network in Ireland

For founders raising in Ireland, GCN provides investor relations infrastructure connecting Irish companies with domestic and international capital, with particular focus on the Series A transition where the domestic market is weakest. Our approach is relationship-led, and we judge our work by whether an introduction still matters two funding rounds later.

For investors seeking Irish exposure, we deliver curated dealflow, diligence support and relationship facilitation across the sectors where Irish companies are strongest. Whether you allocate as a fund, a family office, or a strategic acquirer, our role is to shorten the distance between your mandate and the companies that match it.

To discuss your objectives in Ireland, whether you are based in Dublin, Cork, Galway, or engaging from international markets, our team is available to talk through how we can help.